
In a new FDA study of more than 134,000 Medicare patients, new users of dabigatran (Pradaxa) had a lower risk of clot-related strokes, bleeding in the brain, and death than those taking warfarin. However, dabigatran was associated with a higher risk of major gastrointestinal bleeding than warfarin, according to the FDA’s drug safety communication.
